Retrospective Evaluation of Palifermin Use in Nonhematopoietic Stem Cell Transplant Pediatric Patients

Dazhi Liu, Brian Seyboth, Sherry Mathew, Stephen W. Gilheeney, Alexander Ja-Ho Chou, Esther Drill, Rachel Kobos

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Palifermin has been proven to decrease the frequency of severe oral mucositis in adult patients with sarcoma and metastatic colorectal cancer receiving chemotherapy. The impact of palifermin on the incidence of mucositis in nonhematopoietic stem cell transplantation (HSCT) pediatric population receiving chemotherapy has never been reported to date. Patients and Methods: This is a retrospective analysis of pediatric patients who received palifermin as secondary prophylaxis to prevent chemotherapy-induced mucositis at Memorial Sloan Kettering Cancer Center from January 1, 2008 to 2014. Data from electronic medical records on days to mucositis resolution, use of opioids, use of total parenteral nutrition, duration of hospitalization, and antibiotics are collected and presented here. Results: A total of 18 patients received palifermin for secondary prophylaxis after developing mucositis from the prior chemotherapy cycle. Mucositis did not reoccur in the subsequent cycle for 13 of the 18 patients. The majority of patients who received palifermin prophylaxis had decreased opioids and antibiotics use and decreased duration of hospitalization. Six of the 7 patients previously requiring total parenteral nutrition due to mucositis had decreased supplemental nutritional needs following the use of palifermin. Conclusion: Palifermin may provide benefit as secondary prophylaxis in pediatric patients to prevent chemotherapy-induced mucositis.

Original languageEnglish (US)
Pages (from-to)e177-e183
JournalJournal of Pediatric Hematology/Oncology
Volume39
Issue number4
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Fibroblast Growth Factor 7
Mucositis
Stem Cells
Pediatrics
Transplants
Drug Therapy
Total Parenteral Nutrition
Opioid Analgesics
Hospitalization
Anti-Bacterial Agents
Stomatitis
Electronic Health Records
Stem Cell Transplantation
Sarcoma
Colorectal Neoplasms

Keywords

  • chemotherapy-induced mucositis
  • palifermin
  • secondary prophylaxis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Retrospective Evaluation of Palifermin Use in Nonhematopoietic Stem Cell Transplant Pediatric Patients. / Liu, Dazhi; Seyboth, Brian; Mathew, Sherry; Gilheeney, Stephen W.; Chou, Alexander Ja-Ho; Drill, Esther; Kobos, Rachel.

In: Journal of Pediatric Hematology/Oncology, Vol. 39, No. 4, 01.01.2017, p. e177-e183.

Research output: Contribution to journalArticle

Liu, Dazhi ; Seyboth, Brian ; Mathew, Sherry ; Gilheeney, Stephen W. ; Chou, Alexander Ja-Ho ; Drill, Esther ; Kobos, Rachel. / Retrospective Evaluation of Palifermin Use in Nonhematopoietic Stem Cell Transplant Pediatric Patients. In: Journal of Pediatric Hematology/Oncology. 2017 ; Vol. 39, No. 4. pp. e177-e183.
@article{cec3c688b1c2466582850c1868eea04f,
title = "Retrospective Evaluation of Palifermin Use in Nonhematopoietic Stem Cell Transplant Pediatric Patients",
abstract = "Background: Palifermin has been proven to decrease the frequency of severe oral mucositis in adult patients with sarcoma and metastatic colorectal cancer receiving chemotherapy. The impact of palifermin on the incidence of mucositis in nonhematopoietic stem cell transplantation (HSCT) pediatric population receiving chemotherapy has never been reported to date. Patients and Methods: This is a retrospective analysis of pediatric patients who received palifermin as secondary prophylaxis to prevent chemotherapy-induced mucositis at Memorial Sloan Kettering Cancer Center from January 1, 2008 to 2014. Data from electronic medical records on days to mucositis resolution, use of opioids, use of total parenteral nutrition, duration of hospitalization, and antibiotics are collected and presented here. Results: A total of 18 patients received palifermin for secondary prophylaxis after developing mucositis from the prior chemotherapy cycle. Mucositis did not reoccur in the subsequent cycle for 13 of the 18 patients. The majority of patients who received palifermin prophylaxis had decreased opioids and antibiotics use and decreased duration of hospitalization. Six of the 7 patients previously requiring total parenteral nutrition due to mucositis had decreased supplemental nutritional needs following the use of palifermin. Conclusion: Palifermin may provide benefit as secondary prophylaxis in pediatric patients to prevent chemotherapy-induced mucositis.",
keywords = "chemotherapy-induced mucositis, palifermin, secondary prophylaxis",
author = "Dazhi Liu and Brian Seyboth and Sherry Mathew and Gilheeney, {Stephen W.} and Chou, {Alexander Ja-Ho} and Esther Drill and Rachel Kobos",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/MPH.0000000000000791",
language = "English (US)",
volume = "39",
pages = "e177--e183",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Retrospective Evaluation of Palifermin Use in Nonhematopoietic Stem Cell Transplant Pediatric Patients

AU - Liu, Dazhi

AU - Seyboth, Brian

AU - Mathew, Sherry

AU - Gilheeney, Stephen W.

AU - Chou, Alexander Ja-Ho

AU - Drill, Esther

AU - Kobos, Rachel

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Palifermin has been proven to decrease the frequency of severe oral mucositis in adult patients with sarcoma and metastatic colorectal cancer receiving chemotherapy. The impact of palifermin on the incidence of mucositis in nonhematopoietic stem cell transplantation (HSCT) pediatric population receiving chemotherapy has never been reported to date. Patients and Methods: This is a retrospective analysis of pediatric patients who received palifermin as secondary prophylaxis to prevent chemotherapy-induced mucositis at Memorial Sloan Kettering Cancer Center from January 1, 2008 to 2014. Data from electronic medical records on days to mucositis resolution, use of opioids, use of total parenteral nutrition, duration of hospitalization, and antibiotics are collected and presented here. Results: A total of 18 patients received palifermin for secondary prophylaxis after developing mucositis from the prior chemotherapy cycle. Mucositis did not reoccur in the subsequent cycle for 13 of the 18 patients. The majority of patients who received palifermin prophylaxis had decreased opioids and antibiotics use and decreased duration of hospitalization. Six of the 7 patients previously requiring total parenteral nutrition due to mucositis had decreased supplemental nutritional needs following the use of palifermin. Conclusion: Palifermin may provide benefit as secondary prophylaxis in pediatric patients to prevent chemotherapy-induced mucositis.

AB - Background: Palifermin has been proven to decrease the frequency of severe oral mucositis in adult patients with sarcoma and metastatic colorectal cancer receiving chemotherapy. The impact of palifermin on the incidence of mucositis in nonhematopoietic stem cell transplantation (HSCT) pediatric population receiving chemotherapy has never been reported to date. Patients and Methods: This is a retrospective analysis of pediatric patients who received palifermin as secondary prophylaxis to prevent chemotherapy-induced mucositis at Memorial Sloan Kettering Cancer Center from January 1, 2008 to 2014. Data from electronic medical records on days to mucositis resolution, use of opioids, use of total parenteral nutrition, duration of hospitalization, and antibiotics are collected and presented here. Results: A total of 18 patients received palifermin for secondary prophylaxis after developing mucositis from the prior chemotherapy cycle. Mucositis did not reoccur in the subsequent cycle for 13 of the 18 patients. The majority of patients who received palifermin prophylaxis had decreased opioids and antibiotics use and decreased duration of hospitalization. Six of the 7 patients previously requiring total parenteral nutrition due to mucositis had decreased supplemental nutritional needs following the use of palifermin. Conclusion: Palifermin may provide benefit as secondary prophylaxis in pediatric patients to prevent chemotherapy-induced mucositis.

KW - chemotherapy-induced mucositis

KW - palifermin

KW - secondary prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=85013750152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013750152&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000000791

DO - 10.1097/MPH.0000000000000791

M3 - Article

VL - 39

SP - e177-e183

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 4

ER -